A Retrospective Analysis: Whether Five Factors Affect PFS in Patients With Locally Advanced Cervical Cancer
NCT05779111 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 183
Last updated 2023-03-22
Summary
In previous studies, the investigators found that five factors were effective in predicting the probability of locally advanced cervical cancer with para-aortic lymph node metastasis.A retrospective study was conducted to explore the influence of 5 factors on PFS in patients with locally advanced cervical cancer receiving radiotherapy and chemotherapy.
Conditions
- Locally Advanced Cervical Cancer
- Radiotherapy
Sponsors & Collaborators
-
Chongqing University Cancer Hospital
lead OTHER
Principal Investigators
-
Zou Dongling, M.D. · Chongqing University Cancer Hospital Chongqing, Chongqing, China,
Eligibility
- Min Age
- 18 Years
- Max Age
- 70 Years
- Sex
- FEMALE
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2022-02-10
- Primary Completion
- 2022-11-01
- Completion
- 2022-12-10
Countries
- China
Study Locations
More Related Trials
-
Study of Biomarkers in Tissue Samples From Patients With Metastatic Colon Cancer
NCT01012804 ·Status: WITHDRAWN
-
Observational Study on the Patients With Rectal Cancer
NCT02312284 ·Status: COMPLETED
-
Comparison of Different Subsequent Treatments After Radical Surgery
NCT00806117 ·Status: UNKNOWN ·Phase: PHASE3
-
Biomarkers for Predicting Neoadjuvant Chemoradio-resistance for Middle-low Advanced Rectal Cancer
NCT03573791 ·Status: RECRUITING
-
Retrospective Study of Brachytherapy
NCT05242861 ·Status: RECRUITING
-
Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection
NCT05720559 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Postoperative Hypofractionated Radiation in Cervical and Endometrial Tumours: Phase II Study
NCT05857631 ·Status: RECRUITING ·Phase: NA
-
Survival Outcomes of Uterine Malignancies in Chinese Population
NCT03291275 ·Status: UNKNOWN
-
Clinical Relevance of Major Pathologic Regression for Locally Advanced Rectal Cancer
NCT06879197 ·Status: COMPLETED
-
Short-course Preoperative Chemoradiotherapy Followed by Delayed Operation for Locally Advanced Rectal Cancer
NCT01129700 ·Status: COMPLETED ·Phase: PHASE2
-
Radiation Therapy, Chemotherapy, and Cetuximab Followed by Surgery, Chemotherapy, and Cetuximab in Treating Patients With Locally Advanced or Metastatic Rectal Cancer That Can Be Removed by Surgery
NCT00541112 ·Status: TERMINATED ·Phase: PHASE2
-
Role of Circulating Tumour DNA Testing in Assessing for Alterations of Primary Anti-EGFR Resistance in RAS/RAF Wild-type Metastatic Colorectal Cancer Patients
NCT05051592 ·Status: UNKNOWN
-
Safety of Cetuximab and Trifluridin Tipiracil as the Third-line Therapy in the RASwt mCRC
NCT05155124 ·Status: UNKNOWN ·Phase: PHASE1
-
Lateral Lymph Node Dissection After Neoadjuvant Chemo-radiation in Advanced Low Rectal Cancer
NCT02614157 ·Status: TERMINATED ·Phase: NA
-
A Study to Explore Personalized Treatment for Patients With Recurrent Gynecological Malignancies Based on MTB
NCT06781151 ·Status: RECRUITING
-
Additional Chemotherapy After Neoadjuvant Chemoradiotherapy in Patients With Locally Advanced Rectal Cancer
NCT01671683 ·Status: COMPLETED
-
Perioperative Chemotherapy Plus Cetuximab Versus Chemotherapy Alone for High Risk Resectable Colorectal Liver Metastasis
NCT03031444 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
A Single Arm, Open-label Clinical Trial to Evaluate the Efficacy and Safety of Maintenance Treatment With Capecitabine Plus Cetuximab in Metastatic Colorectal Cancer
NCT02717923 ·Status: UNKNOWN ·Phase: PHASE2
-
4-Point Therapy Response Score With PET/CT for Anal Squamous Cell Cancer
NCT05130073 ·Status: COMPLETED
-
Study of Hypo-fractionated Neoadjuvant Radiotherapy for Locally Advanced Gastric Cancer
NCT03427684 ·Status: UNKNOWN ·Phase: PHASE1/PHASE2
-
Cetuximab in Combination With Anti-PD-1 and mFOLFOX Treat For RAS/BRAF wt Right-Sided Colon Cancer
NCT05468177 ·Status: UNKNOWN ·Phase: PHASE2
-
Efficacy and Safety Study of DC-CIK Cell Therapy Combined With Epaloliposide, Vortexil, and Regorafenib as Third-line Treatment for Advanced Colorectal Cancer.
NCT07343791 ·Status: RECRUITING ·Phase: EARLY_PHASE1
-
Predictive Factors for Outcomes of Fruquintinib Plus Immunotherapy in Colorectal Cancer
NCT05635149 ·Status: UNKNOWN
-
Total Neoadjuvant Therapy With PD-1 for Locally Advcancer Rectal Cancer
NCT07214142 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study
NCT06616259 ·Status: NOT_YET_RECRUITING ·Phase: PHASE3